VentriPoint Diagnostics (TSX VENTURE:VPT) (OTCQX:VPTDF) will be exhibiting at the Annual Meeting of EUROECHO & other Imaging Modalities 2012 from December 5th to 8th in Athens, Greece. VentriPoint is focused on imaging the right heart using low-cost ultrasound to make right-heart diagnostics faster and more cost effective. Starting with 2D ultrasound images, the VentriPoint software uses Knowledge Based Reconstruction (KBR) to calculate accurate right-ventricle volumes and function. Clinical studies have shown that the information from VentriPoint's technique is equivalent to Magnetic Resonance Imaging (MRI), the current standard of care. VentriPoint's booth number is D4.
The VentriPoint technique will be presented at EUROECHO in scientific sessions focused on the analysis of the right ventricle by its many operators, who are leading cardiologists. The strategy of installing at leading institutions is now starting to pay dividends as more and more users incorporate case studies in their presentations. For example; Dr. John Simpson, from Evelina Children's Hospital in London, UK, will be speaking about "Is 2D echo obsolete?" and updating his colleagues about his experience using the VentriPoint VMS(TM) heart analysis system.
"This is VentriPoint's second year attending EUROECHO", said Amol Karnick, VP of Sales and Business Development, "We expect a busy four days as we reconnect with people from last year to show them our progress in developing applications such as pulmonary hypertensions and new hardware changes to make the VMS(TM) more user friendly. Our presence in Europe is growing stronger and we have great relationships with leading institutions to continue our forward momentum".
VentriPoint has 10 installed VMS(TM) heart analysis systems throughout Europe including England, Germany, France, Netherlands, Switzerland, Austria and Norway and has 2 more systems expected to be installed in Europe in 2012. The company is announcing the launch of its German and French versions and it will be adding more languages as it continues to expand within Europe. We have an excellent pipeline of potential customers who are indicating to us their desire to acquire the VMS(TM) as soon as possible in 2013.
The VMS(TM) is approved for clinical use in Canada and Europe and is for investigational use only in the United States.
EUROECHO 2012 is one of the largest echo and imaging meetings in the world and is expected to attract more than 3,000 cardiologists, internists, cardiac surgeons and sonographers from over 90 countries. This year promises four days of the latest science and treatment monitoring options in cardiovascular imaging. Nearly 700 original scientific abstracts will be presented by international scientists on hot topics such as increasing the viability of hearts for transplantation, cardiovascular risks in patients with HIV, the links between obstructive sleep apnea and heart disease, and assessing the cardiac damage induced by cancer drugs.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS(TM) is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children and adults and pulmonary arterial Hypertension are the first applications in a suite of applications for all major heart diseases including cardiovascular disease and heart failure - a multi-billion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS(TM) diagnostic tool and the company is pursuing the US-FDA marketing clearance through the 510(k) process.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
VentriPoint Diagnostics Ltd.
Dr. George Adams
(206) 283-0221, ext. firstname.lastname@example.org